天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 3176-62-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 3176-62-3
Chemical Structure| 3176-62-3
Structure of 3176-62-3 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 3176-62-3 ]

Related Doc. of [ 3176-62-3 ]

Alternatived Products of [ 3176-62-3 ]
Product Citations

Product Citations

Johansson Joel ;

Abstract: As of today, Alzheimer’s disease is the leading cause of dementia among neurodegenerative disorders, affecting many millions of people worldwide. As the average life span of populations increase, more and more people succumb to the illness each year. Like other neurodegenerative disorders, Alzheimer’s disease can be attributed to the accumulation of protein aggregates in the brain. These amyloid-β peptides and tau proteins can presumably be detected in the brain many years before the onset of clinical symptoms. Development of fluorescent ligands, capable of binding to these neuropathological hallmarks and highlighting them, could serve as molecular diagnostic tools and facilitate an early diagnosis of the disease. The method could also be useful in studying disease progression and evaluating the effects of novel treatments. One such ligand is HS-259. The aim of this project was to synthetize different analogues of HS-259, and test their selectivity towards the aforementioned aggregates in brain tissue from an individual with Alzheimer’s disease. Staining of tissue samples with analogue solution enables visualization of aggregate sites through fluorescence imaging. In the end, five analogues were synthetized, albeit in relatively low overall yields. Synthetic methods included Suzuki-Miyara cross-couplings, Ullmann-type arylations and condensations. Liquid Chromatography-Mass Spectrometry (LC-MS) and Nuclear Magnetic Resonance (NMR) were used for analysis of the compounds. Two of the five analogues could be tested for staining of aggregates and assessed for photophysical characteristics, i.e. absorption- and emission spectra. One analogue stained both amyloid-β aggregates and some tau aggregates, whereas the other stained neither. Since only two analogues were tested and rendered inconsistent results, further studies are needed to assess the binding properties of HS-259 analogues in general.

Keywords: Alzheimer's disease ; neurodegenerative disorders ; protein aggregates ; molecular ligands ; amyloid-β ; Aβ ; amyloid-beta ; tau ; diagnosis ; HS-259 ; staining ; brain tissue ; Suzuki coupling ; Ullmann arylation ; condensation ; NMR ; nuclear magnetic resonance ; LC-MS ; liquid chromatography ; neuropathological hallmarks ; absorption spectra ; emission spectra ; synthesis ; plaques ; symptoms ; neuropathology ; thiophene-vinyl-benzothiazole ; TVBT ; ligand analogues ; N-arylation ; Knoevenagel ; preparative LC ; PBS ; phosphate buffered saline ; treatments ; AD ; mechanisms ; thiophene ; benzothiazolium ; fluorescence imaging ; bTVBT ; bi-thiophene-vinyl-benzothiazole ; detection ; Suzuki-Miyara

Purchased from AmBeed:

Product Details of [ 3176-62-3 ]

CAS No. :3176-62-3 MDL No. :MFCD00601361
Formula : C8H8N2 Boiling Point : -
Linear Structure Formula :C7H5(CH3)N2 InChI Key :FWOPJXVQGMZKEP-UHFFFAOYSA-N
M.W : 132.16 Pubchem ID :820804
Synonyms :

Calculated chemistry of [ 3176-62-3 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.12
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 41.06
TPSA : 28.68 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.72 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.18
Log Po/w (XLOGP3) : 1.95
Log Po/w (WLOGP) : 1.87
Log Po/w (MLOGP) : 1.45
Log Po/w (SILICOS-IT) : 2.53
Consensus Log Po/w : 1.8

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.55
Solubility : 0.369 mg/ml ; 0.00279 mol/l
Class : Soluble
Log S (Ali) : -2.18
Solubility : 0.879 mg/ml ; 0.00665 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.26
Solubility : 0.0721 mg/ml ; 0.000546 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.21

Safety of [ 3176-62-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H317-H319-H335 Packing Group:N/A
GHS Pictogram:
Recommend Products
Same Skeleton Products
Historical Records

Related Parent Nucleus of
[ 3176-62-3 ]

Indazoles

Chemical Structure| 4498-74-2

[ 4498-74-2 ]

3-Benzyl-1H-indazole

Similarity: 0.98

Chemical Structure| 1776-37-0

[ 1776-37-0 ]

5-Methyl-1H-indazole

Similarity: 0.89

Chemical Structure| 3176-66-7

[ 3176-66-7 ]

7-Methyl-1H-indazole

Similarity: 0.88

Chemical Structure| 81115-45-9

[ 81115-45-9 ]

5-Amino-6-methyl-1H-indazole

Similarity: 0.86

Chemical Structure| 5757-85-7

[ 5757-85-7 ]

1,3-Dimethyl-1H-indazol-5-amine

Similarity: 0.86

; ;